JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

Search

Cytek Biosciences Inc

Suletud

SektorTervishoid

4.45 1.37

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.29

Max

4.46

Põhinäitajad

By Trading Economics

Sissetulek

-39M

-44M

Müük

9.8M

62M

Kasumimarginaal

-70.929

Töötajad

702

EBITDA

4M

-263K

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+42.05% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

26M

587M

Eelmine avamishind

3.08

Eelmine sulgemishind

4.45

Uudiste sentiment

By Acuity

50%

50%

157 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. apr 2026, 23:15 UTC

Uudisväärsed sündmused

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27. apr 2026, 23:08 UTC

Tulu
Suurimad hinnamuutused turgudel

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27. apr 2026, 23:58 UTC

Tulu

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27. apr 2026, 23:58 UTC

Tulu

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27. apr 2026, 23:56 UTC

Tulu

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27. apr 2026, 23:56 UTC

Tulu

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27. apr 2026, 23:48 UTC

Market Talk

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27. apr 2026, 23:42 UTC

Market Talk

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27. apr 2026, 23:34 UTC

Market Talk
Uudisväärsed sündmused

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27. apr 2026, 23:30 UTC

Market Talk

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27. apr 2026, 23:08 UTC

Market Talk

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27. apr 2026, 23:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. apr 2026, 23:02 UTC

Market Talk

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27. apr 2026, 22:42 UTC

Market Talk

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27. apr 2026, 22:10 UTC

Tulu

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27. apr 2026, 22:09 UTC

Tulu

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27. apr 2026, 22:09 UTC

Tulu

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27. apr 2026, 22:09 UTC

Tulu

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27. apr 2026, 21:56 UTC

Tulu

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27. apr 2026, 21:55 UTC

Tulu

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27. apr 2026, 21:55 UTC

Tulu

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27. apr 2026, 21:44 UTC

Tulu

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27. apr 2026, 21:43 UTC

Tulu

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27. apr 2026, 21:41 UTC

Tulu

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27. apr 2026, 21:41 UTC

Tulu

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27. apr 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. apr 2026, 20:50 UTC

Market Talk
Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

27. apr 2026, 20:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

27. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27. apr 2026, 20:39 UTC

Tulu

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

42.05% tõus

12 kuu keskmine prognoos

Keskmine 6.25 USD  42.05%

Kõrge 7.5 USD

Madal 5 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

1

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

157 / 348 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat